Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. and is urging investors who suffered substantial losses to seek lead plaintiff status by the August 4, 2026 deadline. The lawsuit alleges that GRAIL and certain senior executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, claiming the three-year follow-up period was sufficient to show a statistically significant reduction in late-stage cancer diagnoses while concealing internal indicators that a longer timeline was needed. On February 19, 2026, GRAIL disclosed that the trial failed to meet its primary endpoint and admitted it probably should have allowed for a longer follow-up period, causing shares to plummet 50.55% from $101.53 to $50.21 in a single session and erasing over $2.2 billion in market capitalization. The firm is also investigating when management first recognized the divergence from the touted three-year duration, and encourages whistleblowers with non-public information to come forward.
GRAIL, LLCSecurities fraud class action lawsuit filed against GRAIL over misleading disclosures about NHS-Galleri trial, causing shares to plummet.